AU2001295791A1 - 4-substituted quinolines as antitumor agents - Google Patents

4-substituted quinolines as antitumor agents

Info

Publication number
AU2001295791A1
AU2001295791A1 AU2001295791A AU9579101A AU2001295791A1 AU 2001295791 A1 AU2001295791 A1 AU 2001295791A1 AU 2001295791 A AU2001295791 A AU 2001295791A AU 9579101 A AU9579101 A AU 9579101A AU 2001295791 A1 AU2001295791 A1 AU 2001295791A1
Authority
AU
Australia
Prior art keywords
antitumor agents
substituted quinolines
quinolines
substituted
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295791A
Inventor
Keith Hopkinson Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026747A external-priority patent/GB0026747D0/en
Priority claimed from GB0026745A external-priority patent/GB0026745D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001295791A1 publication Critical patent/AU2001295791A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AU2001295791A 2000-11-02 2001-10-25 4-substituted quinolines as antitumor agents Abandoned AU2001295791A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0026745 2000-11-02
GB0026747 2000-11-02
GB0026747A GB0026747D0 (en) 2000-11-02 2000-11-02 Chemical compounds
GB0026745A GB0026745D0 (en) 2000-11-02 2000-11-02 Chemical compounds
PCT/GB2001/004733 WO2002036570A1 (en) 2000-11-02 2001-10-25 4-substituted quinolines as antitumor agents

Publications (1)

Publication Number Publication Date
AU2001295791A1 true AU2001295791A1 (en) 2002-05-15

Family

ID=26245224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295791A Abandoned AU2001295791A1 (en) 2000-11-02 2001-10-25 4-substituted quinolines as antitumor agents

Country Status (5)

Country Link
US (2) US7253184B2 (en)
EP (1) EP1337513A1 (en)
JP (1) JP2004517059A (en)
AU (1) AU2001295791A1 (en)
WO (1) WO2002036570A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (en) * 2002-11-25 2005-01-14 Wyeth Corp COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004069145A2 (en) * 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP2392564B1 (en) 2003-09-26 2013-10-23 Exelixis, Inc. c-Met modulators and methods of use
KR20070029110A (en) 2003-10-16 2007-03-13 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
GT200500008A (en) * 2004-01-16 2005-08-16 QUINOLINE INTERMEDIARIES AS INHIBITORS OF THIROSINE KINASE RECEPTORS AND THE SYNTHESIS OF THE SAME
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
BR122018075851B1 (en) 2005-11-15 2022-01-11 Array Biopharma Inc COMPOUNDS RELATED TO THE TREATMENT OF HYPERPROLIFERATIVE DISEASE AND PROCESSES FOR PREPARING COMPOUNDS
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
US20090042910A1 (en) * 2006-03-02 2009-02-12 Frederic Henri Jung Quinoline derivatives for treating cancer
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab QUINOLINE DERIVATIVES
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
KR20240011244A (en) 2009-01-16 2024-01-25 엑셀리시스, 인코포레이티드 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US9344401B2 (en) 2009-02-04 2016-05-17 Citrix Systems, Inc. Methods and systems for providing translations of data retrieved from a storage system in a cloud computing environment
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2017040982A1 (en) * 2015-09-02 2017-03-09 The Regents Of The University Of California Her3 ligands and uses thereof
JP7333313B2 (en) * 2017-09-01 2023-08-24 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド Nitrogen-containing heterocyclic compounds, methods of preparation, intermediates, compositions and uses
CN113620875B (en) * 2021-08-13 2023-06-23 郑州大学 3-nitrile quinoline derivative and preparation method thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630489A (en) * 1898-01-12 1899-08-08 Max Deri Alternating-current motor.
SE317376B (en) * 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (en) * 1981-01-16 1982-07-23 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF AMINO-4 CHLORO-7 QUINOLINES
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
ATE159009T1 (en) * 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int BIS MONO- AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH AN INHIBITING EFFECT ON THE EGF AND/OR PDGF RECEPTOR TYROSINKINASE
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06504294A (en) 1991-08-02 1994-05-19 ファイザー・インコーポレーテッド Quinoline derivatives as immunostimulants
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
ATE227283T1 (en) 1996-07-13 2002-11-15 Glaxo Group Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
CA2263479A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as vegf
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
AU757046B2 (en) 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
BR9914164A (en) 1998-09-29 2001-06-26 American Cyanamid Co Compound, method for treating, inhibiting the growth of, or eradicating a neoplasm, and polycystic kidney disease, in a mammal in need thereof, pharmaceutical composition, and, process for preparing a compound
CN1165532C (en) 1998-09-29 2004-09-08 惠氏控股有限公司 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
BR0102116B1 (en) * 2000-05-10 2010-09-21 component for a breathing circuit member.
WO2002044166A1 (en) * 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents

Also Published As

Publication number Publication date
US20080027054A1 (en) 2008-01-31
WO2002036570A1 (en) 2002-05-10
US7253184B2 (en) 2007-08-07
US7504416B2 (en) 2009-03-17
US20050101630A1 (en) 2005-05-12
EP1337513A1 (en) 2003-08-27
JP2004517059A (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2002210714A1 (en) Substituted quinolines as antitumor agents
AU2001295791A1 (en) 4-substituted quinolines as antitumor agents
IL154618A0 (en) Quinolinone derivatives
HK1061810A1 (en) Tetrahydroquinoline derivatives
HK1066218A1 (en) Qunazoline derivatives as antitumor agents
AU2002349676A1 (en) 4-oxoquinoline derivatives
AU2002224595A1 (en) Antitumor agents
AU2002347336A1 (en) Quinoline derivatives
AU2002331707A1 (en) Tetrahydroquinoline derivatives as antithrombotic agents
AU2002347359A1 (en) Quinoline derivatives
GB0104422D0 (en) Quinoline derivative
AU2002338729A1 (en) Router
AU2002346953A1 (en) Protective garment
AU2002363600A1 (en) Novel phenyl-propargylether derivatives
AU2002365664A1 (en) Quinoline derivatives as antitumour agents
AU2002358715A1 (en) Tetrahydrobenzfluorene derivatives
AU2002353755A1 (en) Modesty protector
AU2002255269B8 (en) 2-Iminopyrrolidine derivatives
AU2002313260A1 (en) Antitumor agents
AU2002309041A1 (en) Antitumor agents
AU2002343546A1 (en) Beta-carbolin derivatives as ptp-inhibitors
AU2002258226A1 (en) 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
AU2002335452A1 (en) Antitumor agent
AU2002336502A1 (en) New antitumor agent
AU2002344571A1 (en) Quinoline compound